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PACE Inhibition and Coronary Surgery
Effects of Angiotensin-Converting Enzyme
Inhibitor Therapy on Clinical Outcome in
Patients Undergoing Coronary Artery Bypass Grafting
Antonio Miceli, MD, Radek Capoun, MD, Carlo Fino, MD, Pradeep Narayan, MD,
Alan J. Bryan, MD, Gianni D. Angelini, MD, MCH, Massimo Caputo, MD, MCH
Bristol, United Kingdom
Objectives This study evaluates the effect of pre-operative angiotensin-converting enzyme inhibitor (ACEI) therapy on early
clinical outcomes after coronary artery bypass grafting (CABG).
Background Therapy with ACEIs has been shown to reduce the rate of mortality and prevent cardiovascular events in patients
with coronary artery disease. However, their pre-operative use in patients undergoing CABG is still controversial.
Methods A retrospective, observational, cohort study was undertaken of prospectively collected data on 10,023 consecu-
tive patients undergoing isolated CABG between April 1996 and May 2008. Of these, 3,052 patients receiving
pre-operative ACEI were matched to a control group by propensity score analysis.
Results Overall rate of mortality was 1%. Pre-operative ACEI therapy was associated with a doubling in the risk of death
(1.3% vs. 0.7%; odds ratio [OR]: 2.00, 95% confidence interval [CI]: 1.17 to 3.42; p  0.013). There was also a
significant difference between the ACEI and control group in the risk of post-operative renal dysfunction (PRD)
(7.1% vs. 5.4%; OR: 1.36, 95% CI: 1.1 to 1.67; p  0.006), atrial fibrillation (AF) (25% vs. 20%; OR: 1.34, 95%
CI: 1.18 to 1.51; p  0.0001), and increased use of inotropic support (45.9% vs. 41.1%; OR: 1.22, 95% CI: 1.1
to 1.36; p  0.0001). In a multivariate analysis, pre-operative ACEI treatment was an independent predictor of
mortality (p  0.04), PRD (p  0.0002), use of inotropic drugs (p  0.0001), and AF (p  0.0001).
Conclusions Pre-operative therapy with ACEI is associated with an increased risk of mortality, use of inotropic support, PRD,
and new onset of post-operative AF. (J Am Coll Cardiol 2009;54:1778–84) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.008l
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Cngiotensin-converting enzyme inhibitors (ACEIs) have
een shown to reduce the rate of mortality and to prevent
ardiovascular events in patients with coronary artery disease
1–4), especially after acute myocardial infarction (MI)
5–7). The authors of the EUROPA (European Trial on
eduction of Cardiac Events With Perindopril in Stable
oronary Artery Disease) study (4) showed a 14% reduction
n total rate of mortality, nonfatal MI, unstable angina, and
ardiac arrest. Moreover, in a meta-analysis of 4 trials that
ncluded 98,496 patients with early MI, treatment with
CEI was associated with an average 7% proportional
eduction in mortality within 30 days (5). ACEIs, through
he reduction of angiotensin II and increased bradykinin
vailability, explicate their cardioprotective proprieties on
rom the Bristol Heart Institute, University of Bristol, Bristol, United Kingdom. This
aper was presented at the 58th Annual Scientific Session of the American College of
ardiology, March 28 to 31, 2009, Orlando, Florida.p
Manuscript received February 13, 2009; revised manuscript received June 29, 2009,
ccepted July 8, 2009.eft ventricular afterload and remodeling, improving cardiac
emodynamics, and reducing ventricular mass (3,8,9).
In addition to lowering blood pressure, ACEIs possess a
asculoprotective and anti-ischemic action through their
ntiatherosclerotic, antithrombotic, anti-inflammatory ef-
ects (10–12). Consequently, most patients with coronary
rtery disease receive these drugs. Nevertheless, there are
till significant controversies regarding the pre-operative use
f ACEIs in patients undergoing coronary artery bypass
rafting (CABG). It has been hypothesized by several
uthors (13–16) that the pre-operative administration of
CEI in these patients contributes to lowering of systemic
ascular resistance and vasoplegia in the early post-operative
hase, resulting in hypotension and renal dysfunction.
See page 1785
Authors of the IMAGINE (Ischemia Management With
ccupril Post Bypass Graft via Inhibition of Angiotensin
onverting Enzyme) study (17) reported that, in CABG
atients at low risk of cardiovascular events, routine early
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November 3, 2009:1778–84 ACEI Therapy and CABGnitiation of ACEI therapy does not improve clinical out-
ome up to 3 years after surgery and may increase adverse
vents during the first 3 months. Others authors (18–20)
oncluded that pre-operative treatment with ACEIs does not
ause hypotension and can safely be used in patients
ndergoing cardiac surgery. A national survey in the United
ingdom revealed that the majority of cardiac surgeons
elieve that the use of pre-operative ACEIs increases use of
uids, inotropes, and vasoconstrictors. However, only 39%
f respondents practiced discontinuing the drug before
peration (21). The aim of the present study was, therefore
o review our institutional database to evaluate the effects of
re-operative ACEI treatment on early clinical outcomes
fter CABG.
ethods
atient selection. This was a retrospective, observational,
ohort study of prospectively collected data from consecu-
ive patients who underwent isolated CABG at the Bristol
eart Institute between April 1996 and May 2008. The
tudy was approved by the clinical audit committee of the
niversity Hospital Bristol NHS Foundation Trust, and
ndividual consent was waived. The data collection form is
ntered in a database (Patient Analysis & Tracking System,
Figure 1 Study Profile
ACE  angiotensin-converting enzyme.endrite Clinical Systems, Lon-
on, United Kingdom) and in-
ludes 5 sections that are filled in
onsecutively by anesthetists,
urgeons, the intensive care unit,
he high-dependency unit, and
ard nurses. The base sample
ontained detailed clinical infor-
ation on approximately 10,023
atients. Exclusion criteria were
atients who had unknown
CEI treatment before surgery
nd those with pre-operative car-
iogenic shock. The final sample
ize was 9,274 patients, of which
,730 (51%) received pre-
perative ACEI. To reduce the effect of treatment selection
ias and potential confounding in this observational study,
e used a propensity score-matching analysis to evaluate the
ffect of pre-operative treatment of ACEI on our end points
22). Finally, 3,052 patients on ACEI treatment were
atched to a control group (Fig. 1).
nd points and definitions. The primary end point was
n-hospital mortality, defined as any death occurring within
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
AF  atrial fibrillation
CABG  coronary artery
bypass grafting
CI  confidence interval
MI  myocardial infarction
NYHA  New York Heart
Association
OR  odds ratio
PRD  post-operative renal
dysfunction
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ACEI Therapy and CABG November 3, 2009:1778–840 days of operation. Secondary end points were as follows:
ost-operative renal dysfunction (PRD), atrial fibrillation
AF), MI, stroke, and post-operative inotropic drug use.
re-operative use of an ACEI, including angiotensin recep-
or blockers, was defined as administration within 24 h
efore surgery. Priority of surgery was defined as follows:
mergency (the surgery should be performed within hours
o prevent morbidity or death), urgent (medical factors
equiring the patient to stay in hospital waiting for an
peration), or elective (the clinical status of the patient
llows discharge from hospital with readmission for surgery
t a later date). The decision to perform an off-pump or
n-pump CABG technique was based on individual sur-
eon preference.
A diagnosis of post-operative MI was based on the
resence of Q waves 0.04 ms and/or a reduction in
waves 25% in at least 2 contiguous leads on electrocar-
iogram (ECG). The PRD was defined as a serum creati-
ine level200 mol/l plus an increase of at least 1.5 times
re-operative baseline concentrations. New onset of post-
perative AF was defined as any duration at any time in the
ost-operative period on the basis of a rhythm strip or
2-lead ECG. A diagnosis of stroke was made if there was
vidence of new neurological deficit with morphological
ubstrate confirmed by computed tomography or nuclear
agnetic resonance imaging.
nesthetic, surgical technique, and post-operative man-
gement. Anesthetic and surgical techniques were stan-
ardized for all patients and have been reported previously
23,24). In brief, for patients undergoing on-pump CABG,
ardiopulmonary bypass was instituted with the use of
scending aortic cannulation and 2-stage venous cannula-
ion of the right atrium. The membrane oxygenator was
rimed with 1,000 ml of Hartman’s crystalloid, 500 ml of
elofusine (B. Braun, Melsungin, Germany), 0.5 g/kg
annitol, 7 ml of 10% calcium gluconate, and 6,000 IU
eparin. Alpha-stat pH management was used, and the
ystemic temperature was kept between 34°C and 36°C.
yocardial protection was achieved with intermittent hy-
erkalaemic warm blood cardioplegia. For off-pump CABG
urgery, the Bristol technique was used to expose the
oronaries and provide stabilization to undertake the anas-
omosis (24). At the end of surgery, patients were trans-
erred to the intensive care unit and managed according to
he unit protocol (23,24).
tatistical analysis. Continuous data were expressed as
ean  SD, and categorical data as percentages. The
olmogorov-Smirnov test was used to check for normality
f data in the 2 groups before further analysis. Differences
etween ACEI user and nonuser were compared with the
se of a chi-square test for categorical variables and t or
ilcoxon rank sum tests, as appropriate, for continuous
ariables.
To reduce the effect of selection bias and potential
onfounding in this observational study, we developed a
ropensity score analysis. The propensity for ACEI use was
i
getermined without regard outcomes by the use of a
onparsimonious multiple logistic-regression analysis. All
he variables listed in Table 1 were included in the analysis.
propensity score, indicating the predicted probability of
eceiving ACEI treatment, was then calculated from the
ogistic equation for each patient.
Finally, we used the propensity score to match ACEI
sers to nonusers (1:1 match). Specifically, we matched each
atient with ACEI use to one with non-ACEI use who had
propensity score that was identical to 5 digits. If this could
ot be done, we then proceeded to the next highest digit
atch (4-, 3-, 2-, and 1-digit) to make the best matches, in
hierarchical sequence until no more matches could be
ade. After the propensity score match was performed, we
ssessed differences between the 2 groups with the paired t
est or Wilcoxon signed rank test for continuous variables,
nd McNemars’s test or marginal homogeneity test for
ategorical variables. Conditional logistic regression was
erformed to identify risk factors for rate of mortality, PRD,
ost-operative AF, and post-operative use of inotropic
upport. Results are reported as percentages and odds ratios
aseline Characteristics of the PatientsTable 1 Baseline Characteristics of the Patients
Variable
ACEI
(n  4,730)
No ACEI
(n  4,544) p Value
Demographics
Age, mean (SD), yrs 65.2 (9.1) 64.2 (9.2) 0.0001
Female 844 (17.8) 871 (19.2) 0.106
BSA 1.9 (0.2) 2 (0.2) 0.0001
Cardiovascular risk factors
Hypertension 3,522 (74.5) 2,669 (58.7) 0.0001
Smoker 2,013 (42.6) 2,684 (59.1) 0.0001
Diabetes mellitus 969 (20.5) 507 (11.2) 0.0001
CCS class 3 to 4 2,466 (52) 2,467 (54.3) 0.039
NYHA functional class III to IV 1,150 (32.8) 1,377 (30.3) 0.011
Previous MI 2,771 (58.6) 1,593 (35.1) 0.0001
EF, % 0.0001
Good (50) 3,177 (67.2) 3,627 (79.8)
Fair (3050) 1,241 (26.2) 822 (18.1)
Poor (30) 312 (6.6) 95 (2.1)
History of AF 179 (3.8) 125(2.8) 0.006
COPD 449 (9.5) 404 (8.9) 0.334
Vascular disease 482 (10.2) 393 (8.6) 0.012
Creatinine, mean (SD), mol/l 109.6 (30.7) 110.4 (36.3) 0.2
Redo surgery 116 (2.5) 115 (2.5) 0.861
CAD, mean (SD) 2.63 (0.59) 2.57 (0.63) 0.0001
LMS disease 1,032 (21.8) 839 (18.5) 0.0001
Priority 0.0001
Elective 2,354 (49.8) 2,788 (61.4)
Urgent 2,317 (49) 1,691 (37.2)
Emergent 59 (1.2) 65 (1.4)
No. of grafts, mean (SD) 2.72 (0.78) 2.69 (0.84) 0.094
OPCAB 2,628 (55.6) 1,928 (42.2) 0.0001
alues are expressed as n (%) unless specified otherwise.
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; BSA  body surface
rea; CAD  coronary artery disease; CCS  Canadian Cardiovascular Society; COPD  chronic
bstructive pulmonary disease; EF  ejection fraction; LMS  left main stem; MI  myocardial
nfarction; NYHA  New York Heart Association; OPCAB  off-pump coronary artery bypass
rafting.
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November 3, 2009:1778–84 ACEI Therapy and CABGORs) with 95% confidence interval (CI). All reported p
alues are 2-sided, and p values of0.05 were considered to
ndicate statistical significance. All statistical analysis was
erformed with SPSS version 15.0 (SPSS Inc., Chicago,
llinois) and StatsDirect version 2.7.2 (StatsDirect Ltd.,
hesire, United Kingdom).
esults
atients characteristics and clinical outcomes. Among
,274 patients in the study, 4,730 (51%) were on ACEI
reatment, and 4,544 (49%) were not. Baseline characteris-
ics of the study population are shown in Table 1. ACEI
sers were older and had a greater body surface area; they
ere more likely to have a lower angina functional class,
reater prevalence of hypertension, diabetes, to be non-
mokers, to have vascular and coronary artery disease, as well
s previous history of MI and AF. Patients taking ACEI
ere also more likely to have a lower ejection fraction,
reater New York Heart Association (NYHA) functional
lass, and greater prevalence of urgent operations. Finally,
he prevalence of off-pump procedures was greater in the
CEI users than in nonusers. After performing propensity
core analysis for the entire population, 3,052 patients
eceiving pre-operative ACEI were matched to a control
roup. In the matched cohorts, pre-operative characteristics
nd the use of off pump procedures were similar in both
roups (Table 2).
Overall rate of mortality was 1%. Pre-operative ACEI
herapy was associated with a doubling in the risk of death
1.3%, n  40 vs. 0.7%, n  20, OR: 2.00, 95% CI: 1.17 to
.42; p  0.013). There were a significant difference between
he ACEI and control group in the risk of PDR (7.1%, n 
17 vs. 5.4%, n  167, OR: 1.36, 95% CI: 1.1 to 1.67; p 
.006), AF (25%, 763 patients vs. 20%, 610 patients, OR: 1.34,
5% CI: 1.18 to 1.51; p  0.0001), and use of inotropic
upport (45.9%, n  1,401 vs. 41.1%, n  1,254, OR: 1.22,
5% CI: 1.1 to 1.36; p  0.0001). There were no significant
ifference in post-operative MI (p 0.27) or cerebral events
p  0.26) between the 2 groups (Fig. 2). A conditional
ogistic regression was performed to identify risk factors for
ate of mortality, PRD, post-operative AF, and post-operative
notropic drug support.
ortality. Pre-operative ACEI treatment was an indepen-
ent predictor of mortality (OR: 2.83, 95% CI: 1.03 to 7.8;
 0.04). Other independent risk factors were age and
YHA functional class III to IV (Table 3).
ost-operative use of inotropic support. Multivariate
nalysis showed that ACEI treatment was associated with
n increased use of inotropic support post-operatively (OR:
.17, 95% CI: 1.07 to 1.29; p  0.0001). Additional risk
actors were age, female sex, pre-operative renal function,
edo surgery, numbers of coronaries diseased, left main stem
isease, pre-operative ejection fraction, and nonelective
perations (Table 4). bisk of PRD. The ACEI users had a significant increased
isk of PRD (OR: 1.7, 95% CI: 1.22 to 2.38; p  0.0002).
dditional risk factors for PRD were age, pre-operative renal
unction and NHYA functional class III to IV (Table 5).
ost-operative AF. We found that ACEI therapy was an
ndependent risk factor for post-operative AF (OR: 1.33,
5% CI: 1.17 to 1.51; p  0.0001). Other risk factors were
ge, chronic obstructive pulmonary disease, and history of
F (Table 6).
iscussion
his study demonstrates that pre-operative administration
f ACEI in patients undergoing CABG is associated with a
ignificant increased in perioperative mortality, PRD, AF,
nd use of inotropic support. The effect of ACEI therapy on
arly clinical outcomes in patients undergoing CABG is still
ontroversial. Lazar (25) proposed that the use of ACEI can
enefit patients undergoing cardiac surgery by minimizing
erioperative ischemia and reducing long-term cardiovascu-
ar events, not only for their antihypertensive effects but also
aseline Characteristics ofhe Propensity-Matched PatientsTable 2 B seline Char cteri tics ofthe Propensity-Matched Patients
Variable
ACEI
(n  3,052)
No ACEI
(n  3,052) p Value
Demographics
Age, mean (SD), yrs 64.9 (9.1) 64.8 (9) 0.5
Female 596 (19.5) 589 (19.3) 0.85
BSA 1.94 (0.25) 1.95 (0.28) 0.28
Cardiovascular risk factors
Hypertension 2,070 (67.8) 2,096 (68.7) 0.46
Smoker 1,561 (51.1) 1,533 (50.2) 0.46
Diabetes mellitus 440 (14.4) 430 (14.1) 0.73
CCS class 3 to 4 1,642 (53.8) 1,601 (52.5) 0.3
NYHA functional class III to IV 996 (32.6) 942 (30.9) 0.14
Previous MI 1,417 (46.4) 1,403 (46) 0.7
EF, % 0.2
Good (50) 2,254 (73.9) 2,270 (74.4)
Fair (3050) 673 (22.1) 691 (22.6)
Poor (30) 125 (4.1) 91 (3)
History of AF 93 (3) 100 (3.3) 0.65
COPD 241 (7.9) 242 (7.9) 0.96
Vascular disease 289 (9.5) 292 (9.6) 0.93
Creatinine, mean (SD), mol/l 110.2 (32.9) 109 (31.4) 0.78
Redo surgery 81 (2.7) 84 (2.8) 0.86
CAD, mean (SD) 2.61 (0.61) 2.6 (0.62) 0.45
LMS disease 630 (20.6) 608 (19.9) 0.5
Priority 0.81
Elective 1,715 (56.2) 1,743 (57.1)
Urgent 1,306 (42.8) 1,259 (41.3)
Emergent 31 (1) 50 (1.6)
No. of grafts, mean (SD) 2.7 (0.8) 2.7 (0.82) 0.82
OPCAB 1,496 (49) 1,500 (49.1) 0.94
alues are expressed as n (%) unless specified. By the use of greedy matching, 245 patients were
atched on all 5 digits, 1,114 were matched on 4 digits, 1,151 on 3 digits, 484 on 2 digits, and 58
ere matched on 1 digit. The mean absolute difference in propensity score (SD) between matched
air was 0.00076 (0.0036).
Abbreviations as in Table 1.ecause of their vasculoprotective and antiatherogenic prop-
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ACEI Therapy and CABG November 3, 2009:1778–84rties. He concluded that all patients undergoing CABG
hould receive ACEI pre-operatively with a sensible dosing
egimen that minimizes hypotension. Devbhandari et al.
21) published the result of a United Kingdom national
urvey to address the issue whether it is beneficial or not to
iscontinue ACEI before cardiac surgery. They found that
5% of respondents believed that ACEI should be withheld
efore surgery, and most (63%) believed that their use leads
o vasodilation, resulting in increased use of fluids, ino-
ropes, and vasoconstrictors. However, 65% of surgeons did
ot think that ACEI should be withheld before surgery.
linical outcomes. Our findings that the pre-operative use
f ACEI was an independent predictor of post-operative
notropic support are in line with most published data
13–15,26–29). Bertrand et al. (27) in a small randomized
rial showed that more severe hypotensive episodes requir-
ng vasoconstrictor treatment occur after induction of gen-
ral anesthesia in patients chronically treated with ACEI
nd receiving the drug on the morning before operation, in
omparison with those in whom ACEI were discontinued
n the day before operation. Similar results were reported by
arrel et al. (14), Boeken et al. (28), and Deakin et al. (29),
hereas the authors of other studies (18,19) did not find
uch an association between ACEI treatment and vasople-
ia after cardiac surgery.
Figure 2 Clinical Outcomes in Propensity-Matched Cohort
ACEI  angiotensin-converting enzyme inhibitors; AF  atrial fibrillation; MI  myo
ultivariate Analysis of In-Hospitalor ality in the Propensity-Matched CohortTable 3 Multivariate Analys s of In-H spitalMortality in the Propensity-Matched Cohort
Variable Odds Ratio
95% Confidence
Interval p Value
Age 1.14 1.03–1.26 0.007
ACEI 2.83 1.03–7.8 0.04
NYHA functional class III to IV 4.9 1.14–19.9 0.03Abbreviations as in Table 1.Perioperative hypotension is a well-known risk factor for the
evelopment of PDR in patients undergoing cardiac surgery;
owever, the association between ACEI therapy and PRD
fter cardiac surgery is also controversial (30). Colson et al. (31)
nd Licker et al. (32) showed that creatinine clearance was
aintained among patients who received an acute administra-
ion of ACEI before surgery compared with those receiving
lacebo. However, the effect of ACEI on kidney function may
e different in patients who have been exposed to long-term
CEI treatment. Rady and Ryan (20) did not find a significant
ssociation between ACEI therapy and post-operative renal
ailure in patient undergoing cardiac surgery and chronically
reated with ACEI. This study used quite a severe form of
enal impairment as an end point but did not analyze the
ssociation with less severe renal dysfunction. Arora et al. (16)
n a large observational studied demonstrated a significant
ssociation between pre-operative use of ACEI and acute renal
mpairment after cardiac surgery, and similar results also were
ultivariate Analysis of Post-Operativenotropic Support in the ropensity-Matched CohortTable 4 Multivariate Analysis of Post-OperativeInotropic Support in the Propensity-Matched Cohort
Variable Odds Ratio
95% Confidence
Interval p Value
Age 1.02 1.01–1.03 0.0001
Female 1.32 1.14–1.53 0.0002
ACEI 1.17 1.07–1.29 0.0001
Creatinine, mol/l 1.007 1.004–1.01 0.0001
CAD 1.39 1.21–1.59 0.0001
Left main disease 1.28 1.04–1.58 0.017
EF 50% 1.74 1.41–2.14 0.0001
Redo surgery 1.75 1.07–2.87 0.027
Emergent operations 7.45 3.1–17.8 0.0001
Urgent operations 1.21 1.01–1.45 0.0001
l infarction; PRD  post-operative renal dysfunction.cardiabbreviations as in Table 1.
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November 3, 2009:1778–84 ACEI Therapy and CABGhown after abdominal aortic surgery (33). Our study clearly
howed that ACEI treatment is an independent risk factor for
RD defined as a serum creatinine level200 mol/l plus an
ncrease of at least 1.5 times pre-operative baseline concentra-
ions. It is most likely that this PRD occurs when renal
erfusion pressure cannot be sustained because of substantial
ecreases in mean arterial pressure with an increased use of
asoconstrictor and inotropic drugs.
It has been shown that even a small increase in serum
reatinine after cardiac surgery is associated with increased risk
or deaths in these patients (16,34). Indeed, our data showed
hat pre-operative ACEI therapy increased the risk of death by
-fold in patients undergoing CABG. The fact that other
tudies have failed to demonstrated similar results (20,35) is
ery likely because of inadequate sample size with insufficient
ower to detect differences in mortality, a very infrequent event
fter CABG. In addition, it seems that ACEI therapy may
ncrease adverse events during the first 3 months and does not
mprove clinical outcome up to 3 years after surgery (17).
onversely, authors of the APRES (Angiotensin-Converting
nzyme Inhibition Post Revascularization Study) (36) showed
ong-term treatment with ramipril after invasive revasculariza-
ion significantly reduced the incidence of the composite end
oint of cardiac death, acute MI, or clinical heart failure.
There seems to be increasing evidence to suggest that ACEI
ave the potential to prevent post-operative AF, possibly
ecause of its ability to decrease left atrial stretching secondary
o afterload reduction and atrial remodeling (37,38). However,
t is important to understand that the publication of 2 meta-
nalyses (38,39) did not include any cardiac surgical patients
nd, therefore, the evidence for this potential benefit in cardiac
urgery is weak. A study by White et al. (40) in patients
ndergoing CABG and valve surgery failed to show statisti-
ally significant association between the pre-operative ACEI
se and reduction in post-operative AF events. Our data show
hat ACEI therapy before CABG increases the risk of post-
perative AF in a very large cohort of patients. Contrary to the
tudy by White et al. (40), our study examined only patients
ndergoing CABG and had a much larger sample size.
Pre-operative administration of ACEI in patients undergo-
ng CABG contributes to the lowering of systemic vascular
esistance and vasoplegia in the early post-operative phase,
esulting in hypotension and requiring the administration
f more fluids and inotropic and/or vasoconstrictor drugs
13–15,26–29). It is known that hypotension and volume
verload are risk factors for new onset of post-operative AF
ultivariate Analysis of Post-Operative Renalysfunction in the Propensity-Matched CohortTable 5 Multivariat Analysis of Post-Operative RenalDysfunction in the Propensity-Matched Cohort
Variable Odds Ratio
95% Confidence
Interval p Value
Age 1.06 1.02–1.09 0.0004
ACEI 1.7 1.22–2.38 0.0002
Creatinine, mol/l 1.04 1.03–1.06 0.0001
NYHA functional class III to IV 1.9 1.1–3.28 0.021bbreviations as in Table 1.41). In addition, perioperative use of inotropics and/or vaso-
onstrictor drugs may increase the risk of this arrhythmia after
ardiac surgery (42,43). All these elements, combined with the
ther predisposing and intraoperative risk factors, in presence
f triggers (atrial premature contractions, imbalance of auto-
omic nervous system electrolyte imbalance) might induce the
ew onset of post-operative AF.
tudy limitations. This study is based on the retrospective
nalysis of our large, institutional, observational, prospectively
ollected database. Propensity score analysis is simply a method
or reducing bias in observational studies when randomization
o treatment groups is not possible and the matching was
imited by available variables. Our database did not allow
istinction between the use of ACEIs or angiotensin receptor
lockers, and no information was recorded about the timing
nd specific drug used or dose. We did not consider the years
f surgery as a further potential confounder. However, during
ur study period there were no changes regarding surgical or
naesthetic technique or comorbidities of our patients. The
verall rate of mortality remained approximately 1% during the
tudy period. Finally, although the magnitude of risk associated
ith ACEIs was less than other variables, their contribution is
till significantly relevant to adverse clinical outcome.
onclusions
re-operative ACEI use is associated with worse early clinical
utcomes in patients undergoing CABG. Omitting ACEIs
efore surgery and restarting them post-operatively might be a
easonable approach to improve early outcomes while retaining
he benefits of their cardioprotective effects after CABG.
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